STAT July 25, 2024
Good morning! Before we get to biotech, check out STAT’s deep dive into how UnitedHealth mobilizes a massive network of physicians and milked the health care system for profit.
The need-to-know this morning
- So many earnings reports: AstraZeneca, Roche, Argenx, AbbVie, and Sanofi.
Viking accelerates development of obesity drug that could rival Wegovy, Zepbound
Viking Therapeutics plans to move its injectable obesity treatment into a Phase 3 study faster than expected, bringing the biotech closer to joining the highly competitive GLP-1 drug market.
The San Diego-based biotech previously said it was anticipating the start of a Phase 2b trial of the therapy, VK2735, after getting positive results from a Phase 2 study. But after receiving feedback from regulators,...
Today's Sponsors
Today's Sponsor